Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR013896)
Formula
CYP2C9 ...
SVG example
Unclear
Reactant Losartan Product E 3179
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 2C9 (CYP2C9) DME Info
Cytochrome P450 3A4 (CYP3A4) DME Info
Cytochrome P450 2C9 (CYP2C9) DME Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR013899 Losartan LN1G Unclear - Unclear Losartan [1]
MR013900 Losartan LN2G Unclear - Unclear Losartan [1]
MR013898 Losartan LOG Unclear - Unclear Losartan [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR006913 Losartan potassium Losartan Carboxaldehyde Oxidation - Oxidationn Losartan potassium [2]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR013897 E 3179 E3174 Unclear - Unclear Losartan [2]
MR006914 Losartan Carboxaldehyde Losartan carboxylic acid Unclear Losartan potassium [3]
References
1 The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
2 Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814.
3 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.